clinical trial · NCT07020221
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal CancerSolid Tumor, AdultG12D Mutated KRASVS-7375CetuximabCarboplatin + Pemetrexed + PembrolizumabGemcitabineGemcitabine + Nab-paclitaxel
brief summary
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
started
Jun 24, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Apr 22, 2026
official title
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol